An open-label, flexible-dose, long-term safety and efficacy study of bifeprunox in the treatment of schizophrenia (extension of S154.3.001).

Trial Profile

An open-label, flexible-dose, long-term safety and efficacy study of bifeprunox in the treatment of schizophrenia (extension of S154.3.001).

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Apr 2010

At a glance

  • Drugs Bifeprunox (Primary)
  • Indications Schizophrenia
  • Focus Registrational; Therapeutic Use
  • Sponsors Abbott Laboratories
  • Most Recent Events

    • 07 Sep 2007 Status changed from in progress to completed.
    • 30 Sep 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top